Market Opportunity
The escalating T2D burden in Alberta creates an urgent need for evidence-based remission programs. 398,440 Albertans affected, $556M annual healthcare cost, and concentrated geographic hotspots.
- Prevalence Data
- Growth Projections
- Geographic Hotspots
- Complications
Clinical Foundation
The DiRECT trial provides robust evidence for T2D remission through structured weight loss. 46% remission at 12 months, 86% for those losing 15kg+, proven in routine primary care settings.
- DiRECT Protocol
- Clinical Results
- Long-term Outcomes
- Alberta Adaptation
Competitive Landscape
Strategic positioning against LifestyleRx (virtual competitor), CHANGE Alberta (adjacent model), and incumbent PCN/AHS programs. Defining the unassailable niche through superior execution.
- Competitive Matrix
- Market Gaps
- Differentiation
- Partnership Strategy
Economic Imperative
T2D costs Alberta $556M annually with $27K-$44K per patient over 5 years. DiRECT cost-effectiveness analysis shows £1,337 ($2,496 CAD) lifetime savings per participant, becoming cost-saving within 6 years.
- Healthcare Costs
- Cost-Effectiveness
- ROI Analysis
- Corporate Value
Strategic Moat
Building defensible competitive advantages through behavioral economics, the ThrivePod community system, proprietary digital platform, and the ThriveAB+ cooperative model for long-term patient engagement.
- 3B Framework
- ThrivePod System
- Digital Platform
- Cooperative Model